Skip to main content
Premium Trial:

Request an Annual Quote

Evogene's Sales, Loss Rise in Q1

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evogene today reported that its first-quarter revenues increased nearly 13 year over year, and its loss nearly tripled from the same period a year ago.

The Rehovot, Israel-based firm reported total revenues of $2.7 million for the three-month period ended March 31, 2010, compared to $2.4 million for the first quarter of 2009.

Evogene posted a net loss of $3.7 million, or $.14 per share, compared to a net loss of $1.4 million, or $.06 per share, for the 2009 first quarter.

During the quarter the firm had $3.6 million in financial expenses due to revaluation for accounting purposes of the publicly traded options issued in its 2007 initial public offering.

Evogene's R&D expenses swelled to $939,000 from $340,000 million year over year, while its business development expenses rose to $200,000 from $144,000, and its general and administrative spending increased to $417,000 from $271,000.

Increased R&D expenses were primarily due to the expansion of internal projects, particularly the development to new core computational technologies and staff increases to handle those projects.

Evogene President and CEO Ofer Haviv said in a statement that the R&D enhancements over the quarter included new computational techniques and tools being developed for the Athlete core technology for gene discovery, for the RePack technology for predicting biological regulatory features of genes, and for the EvoBreed technology for accelerating the breeding process.

The firm finished the quarter with $37.8 million in cash, cash equivalents, and short-term bank deposits, and marketable securities.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.